Evonik stock at EUR 21.30, down 1.02% premarket
Published on 11/06/2026 at 08:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat matters for Evonik stock
- Evonik reported its third-quarter 2026 results on November 3.
- The company is expanding production capacity for lipid-based drug delivery in Vancouver.
- The next scheduled quarterly report is set for March 4, 2027.
Evonik stock traded at EUR 21.30 on Lang & Schwarz at 08:10 CET on Friday, November 6, 2026, 1.02 percent below the Xetra close of Thursday, November 5, at EUR 21.52.
Evonik heads into next session
Evonik's investor-relations calendar lists the company's third-quarter 2026 reporting for November 3 and schedules the next quarterly report for March 4, 2027. The dates frame the next major company-specific information points for investors. Further details are available from Evonik Investor Relations.
The company is also expanding its production network for lipid-based drug delivery. Evonik says the planned Vancouver facility will support pharmaceutical and biotechnology customers from development through commercial production.
Investors can follow the real-time quote of Evonik stock during the European session.
European equities will provide the broader market backdrop as investors monitor the DAX.
